Open Access 01-04-2017 | PHASE I STUDIES
A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone
Published in: Investigational New Drugs | Issue 2/2017
Login to get access